Prospectus

EQS-News: CHRONEXT AG: CHRONEXT AG postpones contemplated IPO

Retrieved on: 
Wednesday, October 6, 2021
Publication, European Economic Area, Securities Act of 1933, 10A, Advertising, UBS AG, II, 1997 Constitution of Fiji: Chapter 3, Person, Intention, Prejudice, FSMA, Investor relations, Financial services, Post office box, Urban economics, European Union (Withdrawal) Act 2018, Disclaimer, United Kingdom, UBS, European Union, Finance, Financial Services and Markets Act 2000, EEA, Directive 2014/65/EU, District, Prospectus, Security (finance), Life insurance

A decision to invest in securities of CHRONEXT AG should be based exclusively on the prospectus published by CHRONEXT AG (the "Company") for such purpose.

Key Points: 
  • A decision to invest in securities of CHRONEXT AG should be based exclusively on the prospectus published by CHRONEXT AG (the "Company") for such purpose.
  • Copies of such prospectus (and any supplements thereto) are available free of charge from UBS AG, Swiss Prospectus Switzerland, P.O.
  • CHRONEXT AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
  • Except as required by applicable law, CHRONEXT AG has no intention or obligation to update, keep updated or revise this publication or any parts thereof following the date hereof.

EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs

Retrieved on: 
Wednesday, October 6, 2021
Xi, Adoption, Social media, Securities Act of 1933, Partnership, Review, Failure, Instagram, Deep learning, Name, Therapy, Proxy, Sale, III, FDA, Madison Avenue, Â, Patient, Translation, LinkedIn, Catalog, Ix, Form, Twitter, Drug design, CEO, Communication, Growth, Risk, Technology, PIPE, SEC filing, Bionics, Synthetic biology, Forward-looking statement, Securities Exchange Act of 1934, Investment, Prospectus, Nasdaq, File, Organic acid, SEC, Protein, GLOBE, Pharmaceutical industry, Security (finance), Book

EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.

Key Points: 
  • EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
  • We are excited to work with Absci towards our goal of providing innovative, cost-effective treatment options for patients.
  • This collaboration with EQRx expands the reach of our AI-powered target discovery, drug design and development technology, said Sean McClain, founder and CEO of Absci.
  • EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices.

EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs

Retrieved on: 
Wednesday, October 6, 2021
Technology, Research, Other Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Xi, Adoption, Social media, Securities Act of 1933, Partnership, Review, Failure, Instagram, Deep learning, Name, Therapy, Proxy, Sale, III, FDA, Madison Avenue, Multimedia, Â, Patient, Translation, LinkedIn, Catalog, Ix, Form, Twitter, Drug design, CEO, Communication, Growth, Risk, Technology, PIPE, SEC filing, Bionics, Synthetic biology, Forward-looking statement, Securities Exchange Act of 1934, Investment, Prospectus, Nasdaq, File, Organic acid, SEC, Protein, Pharmaceutical industry, Security (finance), Book, EQRx, Absci, EQRX, ABSCI

EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.

Key Points: 
  • EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
  • We are excited to work with Absci towards our goal of providing innovative, cost-effective treatment options for patients.
  • This collaboration with EQRx expands the reach of our AI-powered target discovery, drug design and development technology, said Sean McClain, founder and CEO of Absci.
  • EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices.

Volcon ePowersports Announces Pricing of Initial Public Offering

Retrieved on: 
Wednesday, October 6, 2021
The Company, Runt, Risk, Security (finance), Sale, Attention, U.S. Securities and Exchange Commission, Nasdaq, Form, Company, Terminology, Telephone, Forward-looking statement, Deer, Prospectus, SEC, Oracle Enterprise Resource Planning Cloud, Risk management

AUSTIN, Texas, Oct. 5, 2021 /PRNewswire/ --Volcon, Inc. (the "Company"), the first all-electric, off-road powersports company, today announced the pricing of its initial public offering of 3,025,000 shares of common stock at a public offering price of $5.50.

Key Points: 
  • AUSTIN, Texas, Oct. 5, 2021 /PRNewswire/ --Volcon, Inc. (the "Company"), the first all-electric, off-road powersports company, today announced the pricing of its initial public offering of 3,025,000 shares of common stock at a public offering price of $5.50.
  • The gross proceeds of the offering are expected to be approximately $16.6 million before deducting underwriting discounts, commissions and offering expenses.
  • In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase up to 226,875 additional shares of common stock at the public offering price to cover over-allotments, if any.
  • If this option is exercised in full, the gross proceeds of the offering would be approximately $17.9 million before deducting underwriting discounts, commissions and offering expenses.

Avalon Acquisition Inc. Announces Pricing of Upsized $180.0 Million Initial Public Offering

Retrieved on: 
Wednesday, October 6, 2021
Avalon, Park Avenue, Risk, Sale, U.S. Securities and Exchange Commission, SEC, Nasdaq, Acquisition, Company, SAN, IPO, EDGAR, Forward-looking statement, Prospectus, Industry, GLOBE, Security (finance)

The units are expected to be listed on the Nasdaq Global Market (Nasdaq) and trade under the ticker symbol AVACU beginning October 6, 2021.

Key Points: 
  • The units are expected to be listed on the Nasdaq Global Market (Nasdaq) and trade under the ticker symbol AVACU beginning October 6, 2021.
  • The Company has granted the underwriters a 45-day option to purchase up to 2,700,000 additional units at the initial public offering price to cover over-allotments, if any.
  • A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the SEC) on October 5, 2021.
  • This press release contains statements that constitute forward-looking statements, including with respect to the Companys initial public offering (IPO) and search for an initial business combination.

Air Lease Corporation Announces Pricing of $300 Million Offering of Preferred Stock

Retrieved on: 
Wednesday, October 6, 2021
Professional Services, Air, Transport, Aerospace, Manufacturing, Finance, J.P. Morgan & Co., III, Security (finance), Sale, RBC Capital Markets, Private Securities Litigation Reform Act, USA, U.S. Securities and Exchange Commission, Air Lease Corporation, Company, LLC, Prospectus, BofA Securities, Mizuho Securities, La règle de non-cumul, NYSE, EDGAR, SEC

Air Lease Corporation (NYSE: AL) (the Company) announced the pricing today of its public offering of 300,000 shares (the Shares) of 4.125% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C (the Series C Preferred Stock), with a liquidation preference of $1,000.00 per share.

Key Points: 
  • Air Lease Corporation (NYSE: AL) (the Company) announced the pricing today of its public offering of 300,000 shares (the Shares) of 4.125% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C (the Series C Preferred Stock), with a liquidation preference of $1,000.00 per share.
  • The sale of the Shares is expected to close on October 13, 2021, subject to satisfaction of customary closing conditions.
  • The Company will pay dividends on the Shares when, as and if declared by the board of directors (or a duly authorized committee of the board of directors).
  • BofA Securities, Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering of the Shares.

Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

Retrieved on: 
Wednesday, October 6, 2021
Xenon, 808, Madison Avenue, State Street, Securities Act of 1933, Suite, Security (finance), Sale, RBC Capital Markets, Private Securities Litigation Reform Act, Attention, U.S. Securities and Exchange Commission, Montgomery Street, Company, LLC, Equity capital markets, SVB Leerink, Telephone, Jefferies Group, Securities Exchange Act of 1934, Prospectus, Jefferies, Nasdaq, SEC, Vesey Street, GLOBE

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.

Key Points: 
  • The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.
  • In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,525,423 common shares at the public offering price, less the underwriting discounts and commissions.
  • The offering is expected to close on or about October 8, 2021, subject to customary closing conditions.
  • These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering.

Nuvei Announces Pricing of Upsized Initial Public Offering in the United States

Retrieved on: 
Wednesday, October 6, 2021
MONTRAL, Risk factor (finance), Syndicate, TSX, Toronto Stock Exchange, RBC Capital Markets, Keefe, Bruyette & Woods, Sale, Attention, U.S. Securities and Exchange Commission, USA, Credit Suisse, Company, Broadridge Financial Solutions, Phrase, International Data Group, Private Securities Litigation Reform Act, Offering, Terminology, LLC, SEDAR, BMO Capital Markets, Intelligence, Scotiabank, Floor, Telephone, Nasdaq, J. P. Morgan, Time, Prospectus, EDGAR, SEC, Vesey Street, Security (finance)

MONTRAL, Oct. 5, 2021 /PRNewswire/ - Nuvei Corporation ("Nuvei" or the "Company") (TSX: NVEI)(TSX: NVEI.U), the global payment technology partner of thriving brands, has announcedtoday the pricing of its upsized marketed offering of3,000,000 subordinate voting shares of the Company in the UnitedStates and Canada, representing Nuvei's initial public offering in the United States (the "Offering").

Key Points: 
  • MONTRAL, Oct. 5, 2021 /PRNewswire/ - Nuvei Corporation ("Nuvei" or the "Company") (TSX: NVEI)(TSX: NVEI.U), the global payment technology partner of thriving brands, has announcedtoday the pricing of its upsized marketed offering of3,000,000 subordinate voting shares of the Company in the UnitedStates and Canada, representing Nuvei's initial public offering in the United States (the "Offering").
  • Nuvei applied to voluntary delist, conditional upon closing of the Offering, its "NVEI.U" US dollar listing on the Toronto Stock Exchange (the "TSX").
  • It is expected that the delisting will be effective after markets close on or about October 13, 2021.
  • Nuvei expects to use the net proceeds from the Offering primarily to strengthen the Company's financial position and allow it to pursue its growth strategies.

INDUS Announces Upsize and Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, October 6, 2021
Press release, REIT, 2nd Floor (Nina song), Security (finance), Form S-3, Sale, Private Securities Litigation Reform Act, Attention, U.S. Securities and Exchange Commission, JMP, Varick Street, Broadridge Financial Solutions, Form, Morgan Stanley, Acquisition, Baird, Company, BMO Capital Markets, Telephone, Prospectus, Nasdaq, EDGAR, SEC, Database, GLOBE, Property management

NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (INDUS or the Company), a U.S. based industrial/logistics REIT, today announced the upsize and pricing of its public offering of 2,150,000 shares of its common stock at a price to the public of $66.00 per share.

Key Points: 
  • NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (INDUS or the Company), a U.S. based industrial/logistics REIT, today announced the upsize and pricing of its public offering of 2,150,000 shares of its common stock at a price to the public of $66.00 per share.
  • The underwriters also have been granted a 30-day option to purchase up to an additional 322,500 shares of common stock from INDUS at the public offering price, less underwriting discounts and commissions.
  • INDUS intends to use the net proceeds from the proposed offering to finance its acquisition and development pipeline and for other corporate purposes.
  • J.P. Morgan and Baird are acting as bookrunners and BTIG, BMO Capital Markets and JMP Securities are acting as co-managers for the offering.

Hess Midstream LP Announces Upsizing and Pricing of Secondary Public Offering of Class A Shares

Retrieved on: 
Wednesday, October 6, 2021
Oil, Gas, Energy, Sale, Water, Securities Act of 1933, Forward-looking statement, Prospectus, Risk, Hess Corporation, SEC, Security (finance)

The Class A shares are being offered and will be sold pursuant to an effective shelf registration statement that was previously filed with the SEC.

Key Points: 
  • The Class A shares are being offered and will be sold pursuant to an effective shelf registration statement that was previously filed with the SEC.
  • The offering is being made only by means of a prospectus and related prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
  • HESM is a fee-based, growth-oriented midstream company that owns, operates, develops and acquires a diverse set of midstream assets to provide services to Hess Corporation and third-party customers.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.